P53 suppresses cytokine induced, Stat5 mediated activation of transcription

Molecular and Cellular Endocrinology

Volumn 143, Issue 1-2, 1998, Pages 143-154

  Fritsche, Michael ^a   Mundt, Maren ^a   Merkle, Christian ^a   Jähne, Ruth ^a   Groner, Bernd ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Cytokine; p53; Prolactin repression; Signal transduction; Stat5; Tumor suppressor

Indexed keywords

BETA CASEIN; CYTOKINE; DNA BINDING PROTEIN; GAMMA INTERFERON; LUCIFERASE; PROLACTIN; PROTEIN P53; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPORTER GENE; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; COS CELLS; CYTOKINES; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; MILK PROTEINS; MUTATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0345368061     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00140-3     Document Type: Article

References (63)

1. Baffy, G., Miyashita, T., Williamson, J.R., Reed, J.C., 1993. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J. Biol. Chem. 268, 6511-6519.
2. Barak, Y., Juven, T., Haffner, R., Oren, M., 1993. mdm2 Expression is induced by wild type p53 activity. Embo J. 12, 461-468.
3. Caelles, C., Helmberg, A., Karin, M., 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes [see comments]. Nature 370, 220-223.
4. Canman, C.E., Gilmer, T.M., Coutts, S.B., Kastan, M.B., 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9, 600-611.
5. Chen, X., Ko, L.J., Jayaraman, L., Prives, C., 1996. p53 levels, functional domains, and Dna damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451.
6. Collins, M.K., Marvel, J., Malde, P., Lopez-Rivas, A., 1992. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J. Exp. Med. 176, 1043-1051.
7. Donehower, L.A., Harvey, M., Slagle, B.L., et al., 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
8. el-Deiry, W.S., Tokino, T., Velculescu, V.E., et al., 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
9. Fritsche, M., Haessler, C., Brandner, G., 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents [published erratum appears in Oncogene 1993 Sep;8(9):2605]. Oncogene 8, 307-318.
10. Gill, G., Ptashne, M., 1988. Negative effect of the transcriptional activator GAL4. Nature 334, 721-724.
11. Gottlieb, E., Haffner, R., von Ruden, T., Wagner, E.F., Oren, M., 1994. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. Embo J. 13, 1368-1374.
12. Gouilleux, F., Moritz, D., Humar, M., Moriggl, R., Berchtold, S., Groner, B., 1995. Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinology 136, 5700-5708.
13. Gouilleux, F., Wakao, H., Mundt, M., Groner, B., 1994. Prolactin induces phosphorylation of Tyr694 of StatS (MGF), a prerequisite for DNA binding and induction of transcription. Embo J. 13, 4361-4369.
14. Gualberto, A., Baldwin, A.S. Jr., 1995. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the Hiv-1 long terminal repeat. J. Biol. Chem. 270, 19680-19683.
15. Halazonetis, T.D., Davis, L.J., Kandil, A.N., 1993. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. Embo J. 12, 1021-1028.
16. Happ, B., Groner, B., 1993. The activated mammary gland specific nuclear factor (MGF) enhances in vitro transcription of the beta-casein gene promoter. J. Steroid Biochem. Mol. Biol. 47, 21-30.
17. Henning, W., Rohaly, G., Kolzau, T., Knippschild, U., Maacke, H., Deppert, W., 1997. MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection [in process citation]. J. Virol. 71, 7609-7618.
18. Hupp, T.R., Lane, D.P., 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4, 865-875.
19. Ihle, J.N., 1996. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Adv. Cancer Res. 68, 23-65.
20. Kastan, M.B., Kuerbitz, S.J., 1993. Control of G1 arrest after DNA damage. Environ. Health Perspect. 101 (Suppl. 5), 55-58.
21. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., Craig, R.W., 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
22. Kastan, M.B., Zhan, Q., el-Deiry, W.S., et al., 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.
23. Kern, S.E., Kinzler, K.W., Bruskin, A., et al., 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711.
24. Kinoshita, T., Yokota, T., Arai, K., Miyajima, A., 1995. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. Embo J. 14, 266-275.
25. Klein-Hitpass, L., Cato, A.C., Henderson, D., Ryffel, G.U., 1991. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19 (6), 1227-1234.
26. Ko, L.J., Prives, C., 1996. p53: Puzzle and paradigm. Genes Dev. 10, 1054-1072.
27. Kristjuhan, A., Maimets, T., 1995. Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. Eur. J. Biochem. 234, 827-831.
28. Kugler, W., Kaling, M., Ross, K., Wagner, U., Ryffel, G.U., 1990. BAP, a rat liver protein that activates transcription through a promoter element with similarity to the USF/MLTF binding site. Nucleic Acids Res. 18, 6943-6951.
29. Levine, A.J., 1997. p53, The cellular gatekeeper for growth and division. Cell 88, 323-331.
30. Lin, J., Chen, J., Elenbaas, B., Levine, A.J., 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246.
31. Liu, X., Robinson, G.W., Gouilleux, F., Groner, B., Hennighausen, L., 1995. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA 92, 8831-8835.
32. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., Jacks, T., 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes [see comments]. Nature 362, 847-849.
33. Lu, H., Levine, A.J., 1995. Human TAF1131 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92, 5154-5158.
34. Mack, D.H., Vartikar, J., Pipas, J.M., Laimins, L.A., 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363, 281-283.
35. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G., Haber, D.A., 1995. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9, 2143-2156.
36. Maiyar, A.C., Phu, P.T., Huang, A.J., Firestone, G.L., 1997. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol. Endocrinol. 11, 312-329.
37. Merkle, C., Fritsche, M., Mundt, M., Jaehne, R., Groner, B., 1998. The carboxyl-terminal regulatory and oligomerization domain of p53 contributes to the specificity and extent of gene transcription and is essential for the induction of apoptosis. Gene Therapy, in press.
38. Merlo, G.R., Venesio, T., Taverna, D., Marte, B.M., Callahan, R., Hynes, N.E., 1994. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene 9, 443-453.
39. Miyashita, T., Reed, J.C., 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
40. Moriggl, R., Berchtold, S., Friedrich, K., et al., 1997. Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Mol. Cell. Biol. 17, 3663-3678.
41. Mundt, M., Hupp, T., Fritsche, M., et al., 1997. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15, 237-244.
42. O'Connor, D.J., Lam, E.W., Griffin, S., et al., 1995. Physical and functional interactions between p53 and cell cycle cooperating transcription factors, E2F1 and DP1. EMBO J. 14, 6184-6192.
43. Okamoto, K., Beach, D., 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. Embo J. 13, 4816-4822.
44. Owen-Schaub, L.B., Zhang, W., Cusack, J.C., et al., 1995. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15, 3032-3040.
45. Pallard, C., Gouilleux, F., Benit, L., et al., 1995a. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. Embo J. 14, 2847-2856.
46. Pallard, C., Gouilleux, F., Charon, M., Groner, B., Gisselbrecht, S., Dusanter-Fourt, I., 1995b. Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. J. Biol. Chem. 270, 15942-15945.
47. Pellegrini, S., Dusanter-Fourt, I., 1997. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur. J. Biochem. 248, 615-633.
48. Pfitzner, E., Jaehne, R., Wissler, M., Stoecklin, E., Groner, B., 1998. p300/CBP enhances the prolactin mediated transcriptional induction through direct interaction with the transactivation domain of StatS, but does not participate in the StatS mediated suppression of the glucocorticoid response. Submitted for publication.
49. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., Aloni, Y., 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8, 1183-1193.
50. Roemer, K., Mueller-Lantzsch, N., 1996. p53 Transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Oncogene 12, 2069-2079.
51. Sang, B.C., Chen, J.Y., Minna, J., Barbosa, M.S., 1994. Distinct regions of p53 have a differential role in transcriptional activation and repression functions. Oncogene 9, 853-859.
52. Shen, Y., Shenk, T., 1994. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc. Natl. Acad. Sci. U S A 91, 8940-8944.
53. Shivakumar, C.V., Brown, D.R., Deb, S., Deb, S.P., 1995. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol. Cell. Biol. 15, 6785-6793.
54. Thut, C.J., Chen, J.L., Klemm, R., Tjian, R., 1995. p53 Transcriptional activation mediated by coactivators Tafii40 and Tafii60. Science 267, 100-104.
55. Truant, R., Xiao, H., Ingles, C.J., Greenblatt, J., 1993. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J. Biol. Chem. 268, 2284-2287.
56. Unger, T., Mietz, J.A., Scheffner, M., Yee, C.L., Howley, P.M., 1993. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol. 13, 5186-5194.
57. Wagner, A.J., Kokontis, J.M., Hay, N., 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8, 2817-2830.
58. Wakao, H., Gouilleux, F., Groner, B., 1994. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response [published erratum appears in EMBO J. 1995 Feb 15;14(4):854-5]. Embo J. 13, 2182-2191.
59. Wakao, H., Schmitt-Ney, M., Groner, B., 1992. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kDa. J. Biol. Chem. 267, 16365-16370.
60. Wang, Y.F., Yu-Lee, L.Y., 1996. Multiple stat complexes interact at the interferon regulatory factor-1 interferon-gamma activation sequence in prolactin-stimulated Nb2 T cells. Mol. Cell. Endocrinol. 121, 19-28.
61. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., Oren, M., 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
62. Zambetti, G.P., Bargonetti, J., Walker, K., Prives, C., Levine, A.J., 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6, 1143-1152.
63. Zhao, J., Schmieg, F.I., Simmons, D.T., Molloy, G.R., 1994. Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene. Mol. Cell. Biol. 14, 8483-8492.